TARS
Company Description
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | 0 | 0 | 0 |
| Net Income | (66.42M) | (115.55M) | (135.89M) | (62.09M) | (13.83M) | (26.81M) | (4.67M) | (1.32M) |
| EPS | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Free Cash Flow | (22.31M) | (84.59M) | (123.00M) | (49.54M) | 3.16M | (21.59M) | (3.85M) | (1.19M) |
| FCF / Share | -0.53 | -2.25 | -4.19 | -2.01 | 0.15 | -1.06 | -0.20 | -0.28 |
| Operating CF | (12.45M) | (83.03M) | (117.49M) | (49.03M) | 3.75M | (21.14M) | (3.67M) | (1.18M) |
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M | 171.97M | 58.32M | 2.39M |
| Total Debt | 93.64M | 72.45M | 30.22M | 20.21M | 1.89M | 831,000 | 164,000 | 0 |
| Cash & Equiv | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M | 168.13M | 57.95M | 2.35M |
| Book Value | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M | 165.98M | (6.00M) | (1.35M) |
| Return on Equity | -0.19 | -0.51 | -0.69 | -0.32 | -0.08 | -0.16 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.91M | 162.05M | 151.67M | 118.70M | 102.66M | 78.33M | 66.41M | 48.12M | 40.81M | 27.61M | 13.08M | 1.87M |
| Net Income | (18.55M) | (6.97M) | (8.37M) | (12.59M) | (20.34M) | (25.12M) | (23.11M) | (23.42M) | (33.29M) | (35.73M) | (41.90M) | (39.15M) |
| EPS | -0.43 | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 |
| Free Cash Flow | 62.70M | (30.47M) | 12.97M | 16.35M | (30.39M) | (21.24M) | (27.25M) | (8.93M) | (15.44M) | (37.96M) | (39.34M) | (36.74M) |
| FCF / Share | 1.44 | -0.71 | 0.30 | 0.38 | -0.72 | -0.54 | -0.71 | -0.23 | -0.41 | -1.08 | -1.23 | -1.20 |
| Operating CF | 66.77M | (24.65M) | 19.33M | 18.26M | (29.39M) | (20.65M) | (22.18M) | (8.65M) | (14.40M) | (37.79M) | (39.34M) | (32.36M) |
| Total Assets | 611.14M | 581.13M | 562.16M | 534.56M | 494.99M | 500.75M | 376.99M | 376.30M | 376.84M | 349.28M | 265.49M | 268.33M |
| Total Debt | 88.66M | 88.68M | 93.64M | 82.51M | 72.45M | 72.37M | 72.45M | 72.34M | 72.18M | 30.52M | 30.22M | 30.13M |
| Cash & Equiv | 204.59M | 102.19M | 183.64M | 112.72M | 96.65M | 175.79M | 94.82M | 176.21M | 181.09M | 193.71M | 224.95M | 226.67M |
| Book Value | 346.73M | 348.95M | 343.43M | 335.08M | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M | 213.66M |
| Return on Equity | -0.05 | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 | -0.10 | -0.10 | -0.13 | -0.13 | -0.21 | -0.18 |
